EdgeRock Capital’s Biogen BIIB Stock Holding History

EdgeRock Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-15	Closed	-$3.66K	–	104
2023 Q4	$3.66K	Buy	+15	New	+$3.68K	﹤0.01%	256
2022 Q4	–	Sell	-15	Closed	-$4K	–	96
2022 Q3	$4K	Buy	+15	New	+$3.19K	﹤0.01%	251

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EdgeRock Capital's BIIB Position: Q1 2024 in Review

EdgeRock Capital sold out of Biogen (BIIB) in Q1 2024, closing a stake of 15 shares — an estimated $3.66K sold.

EdgeRock Capital first reported a position in BIIB in Q3 2022 and held it in 2 quarters. The position peaked at $4K in Q3 2022. 954 funds tracked by Wall St. Rank hold BIIB as of Q1 2024.

EdgeRock Capital reported no remaining Biogen position as of Q1 2024 after selling out during the quarter.
EdgeRock Capital sold 15 Biogen shares in Q1 2024, an estimated $3.66K.
EdgeRock Capital first reported a position in Biogen in Q3 2022 and held it in 2 quarters.
EdgeRock Capital's Biogen position peaked at $4K in Q3 2022.
954 funds tracked by Wall St. Rank held Biogen as of Q1 2024.

Based on EdgeRock Capital's 13F filing for Q1 2024, filed 15 May 2024.